Accelerator Laboratory Services: The Biomarker Powerhouse 

From Discovery to Clinical Impact Across Biofluids and Tissue

Biomarker development has never been more important, or more complex. As therapies become increasingly targeted and clinical trials demand greater precision, researchers and biopharma organizations face a common challenge: how to transform promising biomarker concepts into validated, clinically actionable insights that can accelerate decision-making and improve patient outcomes.

That challenge is exactly why Quanterix created the Accelerator Laboratory.

The Accelerator is more than a testing laboratory. It is a collaborative biomarker services organization designed to help researchers, biotechnology companies, pharmaceutical organizations, academic medical centers, and clinical research groups move seamlessly from biomarker discovery to translational execution and clinical implementation. Built on expertise in ultra-sensitive biomarker detection and spatial biology, the Accelerator serves as a trusted scientific partner capable of supporting programs from early exploratory research through regulated clinical environments.  

One Service Laboratory. Two Modalities. One Integrated Biomarker Strategy.

At its core, the Accelerator operates on a simple but powerful principle: one service laboratory, two biomarker modalities.

Researchers increasingly recognize that understanding disease requires insights from both biofluids and tissue. Blood, serum, plasma, CSF, and other biofluids provide a dynamic view of disease activity, treatment response, and longitudinal changes. Tissue, meanwhile, reveals cellular context, spatial relationships, target expression, and biological mechanisms that cannot be captured through liquid biomarkers alone.

The Accelerator uniquely combines liquid and tissue biomarker expertise within a single organization, providing customers with one partner across the biomarker development continuum.

Through the Simoa Accelerator, customers gain access to ultra-sensitive biomarker detection, custom assay development, validation services, and translational laboratory support across plasma, serum, CSF, blood, and other biofluids. Through the Spatial Accelerator, customers gain access to advanced tissue-based biomarker analysis and spatial proteomics workflows that reveal cellular phenotypes, tissue architecture, target expression, and biological interactions at the cellular level.

Customers may engage the Accelerator for liquid biomarker services, spatial biomarker services, or integrated programs that leverage both modalities within a unified biomarker strategy.

Together, these complementary capabilities enable researchers to generate a more complete understanding of disease biology and therapeutic response while simplifying collaboration through a single scientific partner. From biomarker discovery and assay development to translational research, clinical trials, and diagnostic readiness, the Accelerator is designed to help move programs forward with greater confidence and efficiency.

Built on Experience, Designed for Trust

For years, Quanterix scientists have partnered with customers to solve some of the most challenging biomarker questions in research and clinical development. The laboratory has played a direct role in helping advance biomarker programs that have become foundational to modern precision medicine.

One example is pTau217. Long before it became one of the most important biomarkers in Alzheimer’s disease research, Accelerator scientists worked alongside customers to develop and validate highly sensitive assays capable of measuring the biomarker in plasma. Those collaborations ultimately helped support commercial assay development, laboratory-developed tests, and clinical trial applications that continue to shape the field today.  

The Accelerator’s history matters because biomarker development is rarely straightforward. Success requires scientific expertise, assay development experience, operational excellence, and the ability to anticipate regulatory and clinical requirements long before they become obstacles. The Accelerator brings all these capabilities together in a single organization.

Spatial Accelerator: Turning Tissue Into Actionable Insight

While liquid biomarkers answer many questions, some of the most important answers remain hidden within tissue.

The Spatial Accelerator helps researchers understand the cellular architecture, biological interactions, and tissue-level mechanisms driving disease and treatment response.

Using advanced spatial proteomics technologies and image analyses, the laboratory can evaluate:

• Target expression and distribution
• Cellular phenotypes
• Immune architecture
• Tumor microenvironment interactions
• Treatment response biomarkers
• Resistance mechanisms
• Pharmacodynamic changes within tissue

For oncology researchers, these capabilities are particularly valuable. Spatial assays can quantify target heterogeneity, evaluate tumor-stroma interactions, characterize immune cell localization, and support patient enrichment strategies that extend well beyond traditional single-plex IHC approaches.  

The Spatial Accelerator enables researchers to answer critical questions such as:

• Which patients are most likely to respond?

• How does target expression vary across a tumor?

• What resistance mechanisms are emerging?

• How is the tumor microenvironment changing during therapy?

These insights support smarter translational decisions, stronger clinical trial strategies, and more informed therapeutic development.

Simoa Accelerator: Ultra-Sensitive Biomarker Services Built for Clinical Execution

The Simoa Accelerator provides end-to-end support for liquid biomarker programs, leveraging Quanterix’s industry-leading ultra-sensitive detection technology.

The service portfolio spans four key areas:

Ultra-Sensitive Biomarker Detection
Measure low-abundance proteins across plasma, serum, CSF, and blood with fg/mL sensitivity. This level of performance enables researchers to investigate biomarkers that may be undetectable using conventional technologies.  

Custom Assay Development and Optimization
When commercial assays do not exist, Accelerator scientists work directly with customers to develop and optimize new assays tailored to specific research questions, therapeutic programs, or emerging biomarkers.  

Validation and Clinical Readiness
The team provides fit-for-purpose validation, analytical performance characterization, bridging studies, and regulatory-aligned workflows designed to support translational and clinical execution.  

Clinical Trial Biomarker Support
From longitudinal monitoring to multicenter studies, the Accelerator delivers standardized testing workflows and reporting structures that help generate consistent, reproducible biomarker data across clinical programs.  

 Flexible Service Tiers Designed to Meet Programs Where They Are

Not every biomarker program has the same requirements. Early discovery efforts demand flexibility, while clinical-stage programs require increasing levels of validation, documentation, and regulatory rigor.

To support this progression, the Accelerator offers three service tiers:

RUO (Research Use Only)

Designed for exploratory biomarker discovery, assay evaluation, feasibility studies, and early translational research. This tier allows researchers to investigate new ideas quickly while generating foundational evidence.  

Premium

Designed for organizations requiring enhanced translational support, customized workflows, advanced analytics, scientific consultation, and dedicated project collaboration. Premium programs often represent the critical bridge between exploratory research and clinical implementation.

LDT

Designed for regulated testing environments and clinical-stage biomarker programs. This tier incorporates the analytical validation, quality systems, and documentation necessary to support clinical implementation and laboratory-developed testing strategies.

The tiered approach allows customers to begin where they are today while creating a clear pathway toward future clinical and diagnostic applications.

Capacity, Quality, and Compliance at Scale

The Accelerator combines scientific expertise with operational infrastructure designed to support high-throughput testing, reproducibility, and regulatory readiness. The laboratory operates with a strong commitment to quality systems, supported by CLIA-certified operations, GCLP frameworks, ISO-aligned quality processes, and extensive experience supporting laboratory-developed testing programs.  

This foundation provides customers with:

• Reproducible testing workflows

• Quality-controlled sample processing

• Standardized reporting

• Audit-ready documentation

• Scalable testing capacity

• Confidence in data integrity

For organizations advancing programs toward regulatory submission, clinical trials, or commercial deployment, these capabilities can be just as important as the science itself.

A Partner for Every Stage of the Biomarker Journey

The Accelerator’s mission is straightforward: accelerate the future of precision medicine by transforming biomarker insights from biofluids to tissue, into decisions that move programs forward.  

Whether the goal is discovering a novel biomarker, developing a custom assay, validating a translational workflow, supporting a clinical trial, or preparing for future diagnostic implementation, the Accelerator provides the expertise, technology, and operational rigor required to help customers succeed.

The future of precision medicine will be built on better biomarkers, stronger translational science, and deeper biological understanding.

With one service laboratory, two modalities, and a proven track record of scientific partnership, the Quanterix Accelerator is uniquely positioned to help organizations transform biomarker questions into clinical impact.

Ready to explore what’s possible? Request a consultation with the Quanterix Accelerator team to discuss your biomarker program and how we can accelerate your path from discovery to clinical impact.

Learn more about Spatial Accelerator Services. Explore the entire Quanterix Spatial Ecosystem. 

Explore Simoa Accelerator Services. 

Written by: Shana Tetrault, PhD, Director of Product Marketing